Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 729

1.

An integrated perfusion machine preserves injured human livers for 1 week.

Eshmuminov D, Becker D, Bautista Borrego L, Hefti M, Schuler MJ, Hagedorn C, Muller X, Mueller M, Onder C, Graf R, Weber A, Dutkowski P, Rudolf von Rohr P, Clavien PA.

Nat Biotechnol. 2020 Jan 13. doi: 10.1038/s41587-019-0374-x. [Epub ahead of print]

PMID:
31932726
2.

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases.

Chih-Hsin Yang J, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES.

J Thorac Oncol. 2020 Jan 10. pii: S1556-0864(20)30014-9. doi: 10.1016/j.jtho.2019.12.126. [Epub ahead of print]

PMID:
31931137
3.

A New Mouse Line Reporting the Translation of Brain-Derived Neurotrophic Factor Using Green Fluorescent Protein.

Wosnitzka E, Nan X, Nan J, Chacón-Fernández P, Kussmaul L, Schuler M, Hengerer B, Barde YA.

eNeuro. 2020 Jan 9;7(1). pii: ENEURO.0462-19.2019. doi: 10.1523/ENEURO.0462-19.2019. Print 2020 Jan/Feb.

4.

Sexual minority substance use disparities: Bisexual women at elevated risk relative to other sexual minority groups.

Schuler MS, Collins RL.

Drug Alcohol Depend. 2020 Jan 1;206:107755. doi: 10.1016/j.drugalcdep.2019.107755. Epub 2019 Nov 21.

PMID:
31810051
5.

Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.

Wiesweg M, Herold T, Metzenmacher M, Eberhardt WE, Reis H, Darwiche K, Aigner C, Stuschke M, Herrmann K, Nensa F, Schildhaus HU, Schuler M.

Lung Cancer. 2020 Jan;139:165-168. doi: 10.1016/j.lungcan.2019.11.020. Epub 2019 Nov 26.

PMID:
31809977
6.

Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas.

Salvador-Coloma C, Saigí M, Díaz-Beveridge R, Penín RM, Pané-Foix M, Mayordomo E, Melián M, Schuler M, García Del Muro X, Font de Mora J.

Onco Targets Ther. 2019 Nov 7;12:9265-9275. doi: 10.2147/OTT.S214319. eCollection 2019.

7.

Comment on "The role of electron-electron interactions in two-dimensional Dirac fermions".

Hesselmann S, Lang TC, Schuler M, Wessel S, Läuchli AM.

Science. 2019 Dec 6;366(6470). pii: eaav6869. doi: 10.1126/science.aav6869.

PMID:
31806785
8.

Biomechanical and Metabolic Effectiveness of an Industrial Exoskeleton for Overhead Work.

Schmalz T, Schändlinger J, Schuler M, Bornmann J, Schirrmeister B, Kannenberg A, Ernst M.

Int J Environ Res Public Health. 2019 Nov 29;16(23). pii: E4792. doi: 10.3390/ijerph16234792.

9.

Heterogeneity in Prescription Opioid Pain Reliever Misuse Across Age Groups: 2015-2017 National Survey on Drug Use and Health.

Schuler MS, Dick AW, Stein BD.

J Gen Intern Med. 2019 Dec 2. doi: 10.1007/s11606-019-05559-6. [Epub ahead of print]

PMID:
31792871
10.

Planctopirus ephydatiae, a novel Planctomycete isolated from a freshwater sponge.

Kohn T, Wiegand S, Boedeker C, Rast P, Heuer A, Jetten MSM, Schüler M, Becker S, Rohde C, Müller RW, Brümmer F, Rohde M, Engelhardt H, Jogler M, Jogler C.

Syst Appl Microbiol. 2019 Oct 11:126022. doi: 10.1016/j.syapm.2019.126022. [Epub ahead of print]

PMID:
31785948
11.

Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.

Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B.

Lung Cancer. 2020 Jan;139:124-132. doi: 10.1016/j.lungcan.2019.11.013. Epub 2019 Nov 18.

PMID:
31778960
12.

Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.

Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B.

Cancer Sci. 2019 Nov 28. doi: 10.1111/cas.14254. [Epub ahead of print]

13.

Early Alcohol and Smoking Initiation: A Contributor to Sexual Minority Disparities in Adult Use.

Schuler MS, Collins RL.

Am J Prev Med. 2019 Dec;57(6):808-817. doi: 10.1016/j.amepre.2019.07.020.

PMID:
31753262
14.

Chemically induced aneuploidy in germ cells. Part II of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases.

Pacchierotti F, Masumura K, Eastmond DA, Elhajouji A, Froetschl R, Kirsch-Volders M, Lynch A, Schuler M, Tweats D, Marchetti F.

Mutat Res. 2019 Dec;848:403023. doi: 10.1016/j.mrgentox.2019.02.004. Epub 2019 Mar 20.

PMID:
31708072
15.

Role of aneuploidy in the carcinogenic process: Part 3 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases.

Tweats D, Eastmond DA, Lynch AM, Elhajouji A, Froetschl R, Kirsch-Volders M, Marchetti F, Masumura K, Pacchierotti F, Schuler M.

Mutat Res. 2019 Nov;847:403032. doi: 10.1016/j.mrgentox.2019.03.005. Epub 2019 Mar 29.

PMID:
31699349
16.

Targets and mechanisms of chemically induced aneuploidy. Part 1 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases.

Lynch AM, Eastmond D, Elhajouji A, Froetschl R, Kirsch-Volders M, Marchetti F, Masumura K, Pacchierotti F, Schuler M, Tweats D.

Mutat Res. 2019 Nov;847:403025. doi: 10.1016/j.mrgentox.2019.02.006. Epub 2019 Mar 2.

PMID:
31699346
17.

High information content assays for genetic toxicology testing: A report of the International Workshops on Genotoxicity Testing (IWGT).

Dertinger SD, Totsuka Y, Bielas JH, Doherty AT, Kleinjans J, Honma M, Marchetti F, Schuler MJ, Thybaud V, White P, Yauk CL.

Mutat Res. 2019 Nov;847:403022. doi: 10.1016/j.mrgentox.2019.02.003. Epub 2019 Feb 21.

PMID:
31699343
18.

Application of the adverse outcome pathway framework to genotoxic modes of action.

Sasaki JC, Allemang A, Bryce SM, Custer L, Dearfield KL, Dietz Y, Elhajouji A, Escobar PA, Fornace AJ Jr, Froetschl R, Galloway S, Hemmann U, Hendriks G, Li HH, Luijten M, Ouedraogo G, Peel L, Pfuhler S, Roberts DJ, Thybaud V, van Benthem J, Yauk CL, Schuler M.

Environ Mol Mutagen. 2020 Jan;61(1):114-134. doi: 10.1002/em.22339. Epub 2019 Oct 31.

PMID:
31603995
19.

Effects of nationwide implementation of work-related medical rehabilitation in Germany: propensity score matched analysis.

Bethge M, Markus M, Streibelt M, Gerlich C, Schuler M.

Occup Environ Med. 2019 Dec;76(12):913-919. doi: 10.1136/oemed-2019-106065. Epub 2019 Oct 8.

PMID:
31594839
20.

College attendance type and subsequent alcohol and marijuana use in the U.S.

Jang JB, Schuler MS, Evans-Polce RJ, Patrick ME.

Drug Alcohol Depend. 2019 Nov 1;204:107580. doi: 10.1016/j.drugalcdep.2019.107580. Epub 2019 Sep 22.

21.

Yoga intervention and reminder e-mails for reducing cancer-related fatigue - a study protocol of a randomized controlled trial.

Zetzl T, Schuler M, Renner A, Jentschke E, van Oorschot B.

BMC Psychol. 2019 Sep 18;7(1):64. doi: 10.1186/s40359-019-0339-3.

22.

Capillary electrophoresis with dual detection UV/C4D for monitoring myrosinase-mediated hydrolysis of thiol glucosinolate designed for gold nanoparticle conjugation.

Claude B, Cutolo G, Farhat A, Zarafu I, Ionita P, Schuler M, Tatibouët A, Morin P, Nehmé R.

Anal Chim Acta. 2019 Nov 28;1085:117-125. doi: 10.1016/j.aca.2019.07.043. Epub 2019 Jul 24.

PMID:
31522725
23.

Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians.

Eichler M, Richter S, Hohenberger P, Kasper B, Andreou D, Heidt V, Bornhäuser M, Schmitt J, Schuler MK.

Oncol Res Treat. 2019;42(11):589-598. doi: 10.1159/000502758. Epub 2019 Sep 11.

PMID:
31509840
24.

Question prompts to empower cancer patients: results of a randomized controlled trial.

Zetzl T, Mann D, Gruner S, Schuler M, Jentschke E, Neuderth S, Roch C, van Oorschot B.

Support Care Cancer. 2019 Sep 10. doi: 10.1007/s00520-019-05036-0. [Epub ahead of print]

PMID:
31502228
25.

The lipid metabolism in thraustochytrids.

Morabito C, Bournaud C, Maës C, Schuler M, Aiese Cigliano R, Dellero Y, Maréchal E, Amato A, Rébeillé F.

Prog Lipid Res. 2019 Oct;76:101007. doi: 10.1016/j.plipres.2019.101007. Epub 2019 Sep 6. Review.

PMID:
31499096
26.

Fast and Noninvasive Diagnosis of Cervical Cancer by Coherent Anti-Stokes Raman Scattering.

Aljakouch K, Hilal Z, Daho I, Schuler M, Krauß SD, Yosef HK, Dierks J, Mosig A, Gerwert K, El-Mashtoly SF.

Anal Chem. 2019 Nov 5;91(21):13900-13906. doi: 10.1021/acs.analchem.9b03395. Epub 2019 Sep 17.

PMID:
31483624
27.

[Duration and variation of the ethics approval process in Germany - an example from a non-interventional study with 44 participating centers].

Eichler M, Schmitt J, Schuler MK.

Z Evid Fortbild Qual Gesundhwes. 2019 Oct;146:15-20. doi: 10.1016/j.zefq.2019.07.006. Epub 2019 Aug 29. German.

PMID:
31473073
28.

Primary cell-based phenotypic assays to pharmacologically and genetically study fibrotic diseases in vitro.

Weigle S, Martin E, Voegtle A, Wahl B, Schuler M.

J Biol Methods. 2019 Jun 3;6(2):e115. doi: 10.14440/jbm.2019.285. eCollection 2019.

29.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

PMID:
31405822
30.

The coupling of localised, vibrational modes - Probing OH-bands of organic molecules via a two dimensional Numerov approach.

Schuler MJ, Henn R, Kirchler CG, Schlapp-Hackl I, Huck CW, Hofer TS.

Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jan 5;224:117377. doi: 10.1016/j.saa.2019.117377. Epub 2019 Jul 23.

PMID:
31400743
31.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW.

Oncologist. 2020 Jan;25(1):e160-e169. doi: 10.1634/theoncologist.2019-0297. Epub 2019 Aug 8.

32.

Nutrients influence the multi-trophic impacts of an invasive species unaffected by native competitors or predators.

Hintz WD, Schuler MS, Jones DK, Coldsnow KD, Stoler AB, Relyea RA.

Sci Total Environ. 2019 Dec 1;694:133704. doi: 10.1016/j.scitotenv.2019.133704. Epub 2019 Jul 31.

PMID:
31394331
33.

Substrate-specificity of cytochrome P450-mediated detoxification as an evolutionary strategy for specialization on furanocoumarin-containing hostplants: CYP6AE89 in parsnip webworms.

Calla B, Wu WY, Dean CAE, Schuler MA, Berenbaum MR.

Insect Mol Biol. 2020 Feb;29(1):112-123. doi: 10.1111/imb.12612. Epub 2019 Aug 23.

PMID:
31393031
34.

Bandwidth renormalization due to the intersite Coulomb interaction.

In 't Veld Y, Schüler M, Wehling TO, Katsnelson MI, van Loon EGCP.

J Phys Condens Matter. 2019 Nov 20;31(46):465603. doi: 10.1088/1361-648X/ab36fe. Epub 2019 Jul 30.

PMID:
31362270
35.

Baseline health status and setting impacted minimal clinically important differences in COPD: an exploratory study.

Alma H, de Jong C, Jelusic D, Wittmann M, Schuler M, Kollen B, Sanderman R, Kocks J, Schultz K, van der Molen T.

J Clin Epidemiol. 2019 Dec;116:49-61. doi: 10.1016/j.jclinepi.2019.07.015. Epub 2019 Jul 27.

36.

[Treatment of pain in people with dementia].

Schuler M.

Z Gerontol Geriatr. 2019 Oct;52(6):607-622. doi: 10.1007/s00391-019-01578-4. Epub 2019 Jul 25. German.

PMID:
31346680
37.

Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice.

Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Sanderman R, Schultz K, Kocks J, van der Molen T.

BMJ Open. 2019 Jun 28;9(6):e025776. doi: 10.1136/bmjopen-2018-025776.

38.

[Postoperative mobilization after total hip arthroplasty : Measured by Fitbit activity trackers].

Doppelbauer M, Schüler M, Sauter D.

Orthopade. 2019 Jun 27. doi: 10.1007/s00132-019-03768-9. [Epub ahead of print] German.

PMID:
31250078
39.

Exam Wrapper Use and Metacognition in a Fundamentals Course: Perceptions and Reality.

Schuler MS, Chung J.

J Nurs Educ. 2019 Jul 1;58(7):417-421. doi: 10.3928/01484834-20190614-06.

PMID:
31242311
40.

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M.

Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199.

41.

Changing Roles, Changing Perspectives-Vulnerability as a Patient.

Schuler M.

J Patient Exp. 2019 Mar;6(1):5-6. doi: 10.1177/2374373518769662. Epub 2018 Apr 25.

42.

Nanodiscs as a New Tool to Examine Lipid-Protein Interactions.

Denisov IG, Schuler MA, Sligar SG.

Methods Mol Biol. 2019;2003:645-671. doi: 10.1007/978-1-4939-9512-7_25.

PMID:
31218635
43.

More than pills: alternative adjunct therapies to improve comfort in hospitalised patients.

Moore M, Schuler M, Wilson S, Whisenhunt M, Adams A, Leiker B, Butler T, Shankweiler C, Jones M, Gibson C.

BMJ Open Qual. 2019 May 9;8(2):e000506. doi: 10.1136/bmjoq-2018-000506. eCollection 2019.

44.

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC.

Lung Cancer. 2019 Jul;133:10-19. doi: 10.1016/j.lungcan.2019.04.006. Epub 2019 Apr 8.

45.

Sexual minority disparities in opioid misuse, perceived heroin risk and heroin access among a national sample of US adults.

Schuler MS, Dick AW, Stein BD.

Drug Alcohol Depend. 2019 Aug 1;201:78-84. doi: 10.1016/j.drugalcdep.2019.04.014. Epub 2019 Jun 7.

PMID:
31200278
46.

The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer.

Pastille E, Wasmer MH, Adamczyk A, Vu VP, Mager LF, Phuong NNT, Palmieri V, Simillion C, Hansen W, Kasper S, Schuler M, Muggli B, McCoy KD, Buer J, Zlobec I, Westendorf AM, Krebs P.

Mucosal Immunol. 2019 Jul;12(4):990-1003. doi: 10.1038/s41385-019-0176-y. Epub 2019 Jun 5.

47.

Pre-post changes in main outcomes of medical rehabilitation in Germany: protocol of a systematic review and meta-analysis of individual participant and aggregated data.

Schuler M, Murauer K, Stangl S, Grau A, Gabriel K, Podger L, Heuschmann PU, Faller H.

BMJ Open. 2019 Jun 1;9(5):e023826. doi: 10.1136/bmjopen-2018-023826.

48.

Model assisted analysis of the hepatic arterial buffer response during ex vivo porcine liver perfusion.

Becker D, Hefti M, Schuler M, Bautista Borrego L, Hagedorn C, Muller X, Graf R, Dutkowski P, Tibbitt M, Onder C, Clavien PA, Eshmuminov D, Rudolf von Rohr P.

IEEE Trans Biomed Eng. 2019 May 28. doi: 10.1109/TBME.2019.2919413. [Epub ahead of print]

PMID:
31150329
49.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

50.

Human lung fibroblast-to-myofibroblast transformation is not driven by an LDH5-dependent metabolic shift towards aerobic glycolysis.

Schruf E, Schroeder V, Kuttruff CA, Weigle S, Krell M, Benz M, Bretschneider T, Holweg A, Schuler M, Frick M, Nicklin P, Garnett JP, Sobotta MC.

Respir Res. 2019 May 9;20(1):87. doi: 10.1186/s12931-019-1058-2.

Supplemental Content

Loading ...
Support Center